KBP is developing an innovative pipeline of New Chemical Entities with known mechanisms of action in areas of unmet medical need in Organ Protection and Infectious Diseases.

Pipeline
KBP-5074 for CV disease/Hypertension in CKD patients – Initiating global Phase 2b in Q1 2018

KBP-7072 for multiple drug resistant infections – Finish Phase 1 – Ready for global Phase 2

KBP-7026 novel CRTH2 receptor antagonist targeting asthma/COPD – IND Approved & Ready for Phase 1

Read More

Management Team

• Johan M.(Thijs) Spoor, MBA, CEO
• Fred Yang, PhD, CDO
• Michael Miernicki, PhD, VP
• Vince Benn, PhD/MBA, VP
• Jay (Xu-Jie) Zhang, PhD, VP
• Jerry Zhong, PhD, MBA, PMP, VP
• Pengfei (Murphy) Guo, PhD, AVP
• A. Sophia Hurtado, RN, Senior Director

SCIENTIFIC ADVISORY BOARD 5074
• George Bakris, MD (US)
• John McMurray, MD (UK)
• Bertram Pitt, MD (US)
• Faiez Zannad, MD (FR)
• Frédéric Jaisser, MD, PhD
• Clare Kahn, PhD

SCIENTIFIC ADVISORY BOARD 7072
• Ricard Wunderink, MD (US)

Read More

KBP BIOSCIENCES SIGNS MEMORANDUM OF UNDERSTANDING WITH BULLFROG AI
KBP Biosciences Co., Ltd. attended the 2017 China BioMed Innovation and Investment Conference.

Careers Information updated on 27 July, 2017

Positive FDA Type B Meeting on KBP-5074

KBP-7072 obtained QIDP and Fast Track Designations

Read More

Contact Us

Jennifer Miao          jennifer.miao@kbpbiosciences.com

116 Village Blvd., Suite 210 Princeton, NJ 08540      Phone: (609) 531-0889(Office) / (732)429-0898(Cell)